Mesoblast Limited (LWB) - Total Liabilities
Based on the latest financial reports, Mesoblast Limited (LWB) has total liabilities worth €207.62 Million EUR (≈ $242.73 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mesoblast Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how Mesoblast Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Mesoblast Limited to evaluate short-term liquidity relative to the company's equity base.
Mesoblast Limited Competitors by Total Liabilities
The table below lists competitors of Mesoblast Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sigma Lithium Resources Corp
V:SGML
|
Canada | CA$237.12 Million |
|
Sylvamo Corp
NYSE:SLVM
|
USA | $1.80 Billion |
|
AbraSilver Resource Corp.
TO:ABRA
|
Canada | CA$4.13 Million |
|
Guangdong Homa Appliances Co Ltd
SHE:002668
|
China | CN¥10.64 Billion |
|
Lithium Americas Corp
TO:LAC
|
Canada | CA$990.59 Million |
|
Tootsie Roll Industries Inc
NYSE:TR
|
USA | $298.96 Million |
|
Solvac S.A.
BR:SOLV
|
Belgium | €215.41 Million |
|
ManpowerGroup Inc
NYSE:MAN
|
USA | $6.33 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Mesoblast Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mesoblast Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mesoblast Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mesoblast Limited (2014–2025)
The table below shows the annual total liabilities of Mesoblast Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €187.24 Million ≈ $218.90 Million |
-0.82% |
| 2024-06-30 | €188.80 Million ≈ $220.72 Million |
+12.66% |
| 2023-06-30 | €167.58 Million ≈ $195.92 Million |
+1.50% |
| 2022-06-30 | €165.10 Million ≈ $193.02 Million |
+1.09% |
| 2021-06-30 | €163.32 Million ≈ $190.94 Million |
-11.37% |
| 2020-06-30 | €184.28 Million ≈ $215.44 Million |
+7.72% |
| 2019-06-30 | €171.06 Million ≈ $199.99 Million |
+16.82% |
| 2018-06-30 | €146.44 Million ≈ $171.20 Million |
+5.41% |
| 2017-06-30 | €138.92 Million ≈ $162.41 Million |
-10.87% |
| 2016-06-30 | €155.86 Million ≈ $182.21 Million |
-50.33% |
| 2015-06-30 | €313.78 Million ≈ $366.84 Million |
+1.56% |
| 2014-06-30 | €308.95 Million ≈ $361.20 Million |
-- |
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more